Marieke van Son

76 CHAPTER 4 11. Grimm, P.; Billiet, I.; Bostwick, D.; Dicker, A.P.; Frank, S.; Immerzeel, J.; Keyes, M.; Kupelian, P.; Lee, W.R.; Machtens, S., et al. Comparative analysis of pros- tate-specific antigen free survival outcomes for patients with low, inter- mediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU international 2012, 109 Suppl 1, 22-29; DOI: 10.1111/j.1464- 410X.2011.10827.x. 12. Morton, G.C.; Hoskin, P.J. Brachythera- py: Current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy? Clinical oncology (Royal College of Ra- diologists (Great Britain)) 2013, 25, 474- 482; DOI: 10.1016/j.clon.2013.04.009. 13. Prada, P.J.; Ferri, M.; Cardenal, J.; Blanco, A.G.; Anchuelo, J.; Diaz de Cerio, I.; Vazquez, A.; Pacheco, M.; Raba, I.; Ruiz, S. High-dose-rate inter- stitial brachytherapy as monotherapy in one fraction of 20.5 gy for the treat- ment of localized prostate cancer: Tox- icity and 6-year biochemical results. Brachytherapy 2018; DOI: 10.1016/j. brachy.2018.06.002. 14. Morris, W.J.; Tyldesley, S.; Rodda, S.; Halperin, R.; Pai, H.; McKenzie, M.; Duncan, G.; Morton, G.; Hamm, J.; Murray, N. Androgen suppression com- bined with elective nodal and dose esca- lated radiation therapy (the ascende-rt trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk pros- tate cancer. Int J Radiat Oncol Biol Phys 2017, 98, 275-285; DOI: 10.1016/j. ijrobp.2016.11.026. 15. Zumsteg, Z.S.; Spratt, D.E.; Romesser, P.B.; Pei, X.; Zhang, Z.; Polkinghorn, W.; McBride, S.; Kollmeier, M.; Yamada, Y.; Zelefsky, M.J. The natural history and predictors of outcome following bio- chemical relapse in the dose escalation era for prostate cancer patients under- going definitive external beam radio- therapy. Eur Urol 2015, 67, 1009-1016; DOI: 10.1016/j.eururo.2014.09.028. 16. Wise, A.M.; Stamey, T.A.; McNeal, J.E.; Clayton, J.L. Morphologic and clinical significance of multifocal prostate can- cers in radical prostatectomy speci- mens. Urology 2002, 60, 264-269. 17. Andreoiu, M.; Cheng, L. Multifocal pros- tate cancer: Biologic, prognostic, and therapeutic implications. Human pa- thology 2010, 41, 781-793; DOI: 10.1016/j. humpath.2010.02.011. 18. Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature medicine 2009, 15, 559-565; DOI: 10.1038/nm.1944. 19. Ahmed, H.U. The index lesion and the origin of prostate cancer. N Engl J Med 2009, 361, 1704-1706; DOI: 10.1056/NE- JMcibr0905562. 20. Ahmed, H.U.; Pendse, D.; Illing, R.; Allen, C.; van der Meulen, J.H.; Emberton, M. Will focal therapy become a standard of care for men with localized prostate cancer? Nature clinical practice. On- cology 2007, 4, 632-642; DOI: 10.1038/ ncponc0959. 21. Arrayeh, E.; Westphalen, A.C.; Kurhan- ewicz, J.; Roach, M., 3rd; Jung, A.J.; Carroll, P.R.; Coakley, F.V. Does local re- currence of prostate cancer after radia- tion therapy occur at the site of primary tumor? Results of a longitudinal mri and mrsi study. Int J Radiat Oncol Biol Phys 2012, 82, e787-793; DOI: 10.1016/j. ijrobp.2011.11.030.